|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC2A2 |
Gene summary for SLC2A2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC2A2 | Gene ID | 6514 |
| Gene name | solute carrier family 2 member 2 | |
| Gene Alias | GLUT2 | |
| Cytomap | 3q26.2 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | P11168 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6514 | SLC2A2 | NAFLD1 | Human | Liver | NAFLD | 1.37e-08 | 9.18e-01 | -0.04 |
| 6514 | SLC2A2 | S43 | Human | Liver | Cirrhotic | 2.77e-13 | 1.93e-02 | -0.0187 |
| 6514 | SLC2A2 | S44 | Human | Liver | HCC | 8.45e-04 | 6.21e-01 | -0.0083 |
| 6514 | SLC2A2 | HCC1_Meng | Human | Liver | HCC | 4.22e-23 | -3.62e-01 | 0.0246 |
| 6514 | SLC2A2 | HCC2_Meng | Human | Liver | HCC | 3.52e-14 | -4.35e-01 | 0.0107 |
| 6514 | SLC2A2 | cirrhotic1 | Human | Liver | Cirrhotic | 7.40e-07 | 6.11e-02 | 0.0202 |
| 6514 | SLC2A2 | cirrhotic2 | Human | Liver | Cirrhotic | 1.80e-06 | 3.48e-02 | 0.0201 |
| 6514 | SLC2A2 | cirrhotic3 | Human | Liver | Cirrhotic | 7.71e-03 | -2.69e-01 | 0.0215 |
| 6514 | SLC2A2 | HCC1 | Human | Liver | HCC | 5.04e-44 | 7.60e+00 | 0.5336 |
| 6514 | SLC2A2 | HCC2 | Human | Liver | HCC | 4.56e-29 | 4.94e+00 | 0.5341 |
| 6514 | SLC2A2 | Pt13.a | Human | Liver | HCC | 4.64e-03 | -2.59e-01 | 0.021 |
| 6514 | SLC2A2 | Pt13.b | Human | Liver | HCC | 1.48e-06 | -2.91e-01 | 0.0251 |
| 6514 | SLC2A2 | S015 | Human | Liver | HCC | 2.36e-05 | 6.10e-02 | 0.2375 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0015749 | Liver | NAFLD | monosaccharide transmembrane transport | 21/1882 | 116/18723 | 5.54e-03 | 4.23e-02 | 21 |
| GO:1904659 | Liver | NAFLD | glucose transmembrane transport | 20/1882 | 110/18723 | 6.36e-03 | 4.69e-02 | 20 |
| GO:0034219 | Liver | NAFLD | carbohydrate transmembrane transport | 21/1882 | 118/18723 | 6.77e-03 | 4.79e-02 | 21 |
| GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049316 | Liver | NAFLD | Insulin resistance | 29/1043 | 108/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 29 |
| hsa0493111 | Liver | NAFLD | Insulin resistance | 29/1043 | 108/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 29 |
| hsa052308 | Liver | Cirrhotic | Central carbon metabolism in cancer | 30/2530 | 70/8465 | 1.41e-02 | 4.35e-02 | 2.68e-02 | 30 |
| hsa0492221 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
| hsa0523011 | Liver | Cirrhotic | Central carbon metabolism in cancer | 30/2530 | 70/8465 | 1.41e-02 | 4.35e-02 | 2.68e-02 | 30 |
| hsa0492231 | Liver | Cirrhotic | Glucagon signaling pathway | 43/2530 | 107/8465 | 1.42e-02 | 4.35e-02 | 2.68e-02 | 43 |
| hsa0493121 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa0492241 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
| hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa0523021 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa0493131 | Liver | HCC | Insulin resistance | 77/4020 | 108/8465 | 3.89e-07 | 4.46e-06 | 2.48e-06 | 77 |
| hsa0492251 | Liver | HCC | Glucagon signaling pathway | 64/4020 | 107/8465 | 6.70e-03 | 1.87e-02 | 1.04e-02 | 64 |
| hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| hsa0523031 | Liver | HCC | Central carbon metabolism in cancer | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC2A2 | deletion | Frame_Shift_Del | rs766082034 | c.24delN | p.Thr9ProfsTer22 | p.T9Pfs*22 | P11168 | protein_coding | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | ||
| SLC2A2 | SNV | Missense_Mutation | c.1203N>C | p.Met401Ile | p.M401I | P11168 | protein_coding | tolerated(1) | benign(0.012) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC2A2 | SNV | Missense_Mutation | c.255G>C | p.Glu85Asp | p.E85D | P11168 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-VS-A8EJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| SLC2A2 | SNV | Missense_Mutation | novel | c.1545N>A | p.Met515Ile | p.M515I | P11168 | protein_coding | deleterious(0.03) | benign(0.065) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC2A2 | SNV | Missense_Mutation | novel | c.482N>T | p.Ser161Leu | p.S161L | P11168 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| SLC2A2 | SNV | Missense_Mutation | c.400N>A | p.Leu134Met | p.L134M | P11168 | protein_coding | deleterious(0) | possibly_damaging(0.794) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SLC2A2 | SNV | Missense_Mutation | c.1334N>T | p.Thr445Ile | p.T445I | P11168 | protein_coding | deleterious(0.03) | benign(0.062) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SLC2A2 | SNV | Missense_Mutation | novel | c.327N>T | p.Met109Ile | p.M109I | P11168 | protein_coding | tolerated(0.1) | benign(0.31) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC2A2 | SNV | Missense_Mutation | novel | c.652N>G | p.Trp218Gly | p.W218G | P11168 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SLC2A2 | SNV | Missense_Mutation | novel | c.398N>G | p.Ile133Ser | p.I133S | P11168 | protein_coding | tolerated(0.26) | benign(0.057) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | 178101360 | |||
| 6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | GLUFOSFAMIDE | GLUFOSFAMIDE | ||
| 6514 | SLC2A2 | TRANSPORTER, DRUGGABLE GENOME | metformin | METFORMIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |